Digital Therapeutics (DTx) are evidence-based therapeutic interventions driven by the software to prevent, manage, or treat a medical disorder or disease. Digital Therapeutics are a part of the digital healthcare that deliver therapeutic interventions directly to patients via evidence-based, clinically-evaluated software for disease management.   

Market Dynamics:

Increasing burden of chronic diseases, the outbreak of COVID-19 (pandemic), increasing adoption of patient-centric healthcare apps, growing adoption of digital healthcare solutions or technologies, and increasing focus toward preventive healthcare by governments are major factors expected to augment the growth of the global digital therapeutics market.

For instance, in February 2022, DynamiCare Health Inc. announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Device Designation for the DCH-001, a prescription-only digital therapeutic to treat tobacco use disorder complicating pregnancy and childbirth.

Moreover, in July 2022, AmerisourceBergen planned to launch digital therapeutics (DTx) platform to facilitate access to innovative products. The platform enables doctors to easily access and order prescription and non-prescription DTx through their e-prescribing workflow and monitor patient fulfilment of digital therapeutics and diagnostics.

Key features of the study:

• This report provides in-depth analysis of the global digital therapeutics market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period (2023-2030), considering 2022 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global digital therapeutics market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include Happify, Inc., 2Morrow, Inc., Akili Interactive Labs, Inc., Click Therapeutics, Inc., and Fitbit, Inc. (Twine Health, Inc.).
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• The global digital therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global digital therapeutics market.

Detailed Segmentation:

• Global Digital Therapeutics Market, By Application:
  • Diabetes
  • Obesity
  • Cardiovascular Disease (CVD)
  • Central Nervous System (CNS) Disease
  • Respiratory Disease
  • Smoking Cessation
  • Gastrointestinal Disorder (GID)
  • Others
• Global Digital Therapeutics Market, By Product Type:
  • Software
  • Device
• Global Digital Therapeutics Market, By Sales Channel:
  • Business-to-Business (B2B)
  • Employer
  • Healthcare Provider
  • Others
  • Business-to-Consumer (B2C)
  • Patient
  • Caregiver
• Global Digital Therapeutics Market, By Geography:
  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa
• Company Profiles:
  • Happify, Inc.
  • 2Morrow, Inc.
  • Akili Interactive Labs, Inc.
  • Click Therapeutics, Inc.
  • Fitbit, Inc. (Twine Health, Inc.)